Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback
Eli Lilly's market capitalization has risen following a setback for Kailera's oral GLP-1 obesity drug trials in China.
Sources (9)
- Kailera weight loss pill trial results: nausea sinks stock qz.com · 48d ago
- Kailera Therapeutics Announces Positive Topline Data from GlobeNewswire · 48d ago
- Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending BioSpace · 48d ago
- Kailera's GLP-1 drug meets main goal of late-stage trials Yahoo Finance · 48d ago
- Kailera says obesity pill succeeds in late-stage trial in China BioPharma Dive · 48d ago
- Hengrui, Kailera's GLP-1 pill posts encouraging efficacy but high side effect rates in late-stage China trials Endpoints News · 48d ago
- Kailera shares tumble on high nausea rates despite weight-loss drug's success Reuters · 48d ago
- Kailera’s oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials Fierce Biotech · 48d ago
- Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback Investor's Business Daily · 48d ago broke it first
The brief
Kailera's oral GLP-1 asset achieved its goals in Chinese phase 3 obesity and diabetes trials, demonstrating an 11% weight loss. However, the drug experienced high rates of nausea and other side effects.
Coverage from Reuters, Endpoints News, BioPharma Dive, and Fierce Biotech emphasizes that while the pill showed encouraging efficacy, the side effect profile caused Kailera's shares to tumble. Investor's Business Daily reports that this setback coincided with an increase in Eli Lilly's market capitalization.
Future developments depend on how Kailera addresses the high side effect rates reported in the late-stage trials.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 48d ago.
Quick answers
What were the results of Kailera's late-stage trials in China?
The oral GLP-1 asset hit its goals, with reports of 11% weight loss.
Why did Kailera's shares decline despite the drug's efficacy?
Shares tumbled due to high rates of nausea and other side effects observed during the trials.
How did this news affect Eli Lilly?
According to Investor's Business Daily, Eli Lilly's market cap increased following the setback.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
From around our network
Related trends
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a new Alzheimer’s disease blood test developed by Roche and Eli Lilly.
Typhoon Narra wreaks havoc in China, Vietnam as rains lead to floods
Typhoon Narra triggers widespread flooding across parts of China and Vietnam, stranding residents and prompting emergency evacuations.
A powerful country on the other side of the world is quietly shaping Trump's latest trade fight
5 articles track international trade tensions involving Canada, the United States, India, China, and shifting global security dynamics.
Robot horse and rider steal the spotlight at Chinese conference
A robotic horse and rider grabbed attention at a Chinese conference, standing out among machines that box, mix drinks, and rock.
China Evergrande founder sentenced to life in prison
Evergrande’s founder receives a life sentence, sending shockwaves through China’s property market and creditor landscape.
Researchers find new benefits, risks in GLP-1 weight loss drugs
Scientists uncover unexpected benefits and new risks surrounding widely used GLP-1 weight loss medications.